Wealth Enhancement Advisory Services LLC Has $179.89 Million Stock Position in Abbott Laboratories $ABT

Wealth Enhancement Advisory Services LLC boosted its stake in Abbott Laboratories (NYSE:ABT) by 24.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,338,060 shares of the healthcare product maker’s stock after buying an additional 263,216 shares during the period. Wealth Enhancement Advisory Services LLC owned approximately 0.08% of Abbott Laboratories worth $179,889,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ABT. Brighton Jones LLC grew its position in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Bank Pictet & Cie Europe AG grew its position in shares of Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker’s stock worth $17,274,000 after purchasing an additional 2,774 shares in the last quarter. Vident Advisory LLC grew its position in shares of Abbott Laboratories by 30.2% during the 4th quarter. Vident Advisory LLC now owns 34,899 shares of the healthcare product maker’s stock worth $3,948,000 after purchasing an additional 8,098 shares in the last quarter. Woodline Partners LP acquired a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $5,997,000. Finally, Waverly Advisors LLC grew its position in shares of Abbott Laboratories by 19.1% during the 4th quarter. Waverly Advisors LLC now owns 87,165 shares of the healthcare product maker’s stock worth $9,859,000 after purchasing an additional 13,952 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on ABT. Jefferies Financial Group upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and increased their target price for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Leerink Partnrs upgraded shares of Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Leerink Partners began coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a “market perform” rating and a $143.00 price target on the stock. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research report on Friday, July 18th. Finally, Morgan Stanley increased their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $144.47.

Abbott Laboratories Price Performance

ABT stock opened at $133.90 on Thursday. The company has a fifty day moving average price of $130.36 and a 200-day moving average price of $131.24. The company has a market capitalization of $233.05 billion, a P/E ratio of 16.78, a PEG ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.